The Unique Structure
When looking at the pharmaceutical development industry, there is one company who shows a more significant impact and rate of success than any other company of its size. That company, is likely as successful as it is because of the unique structure devised by founder Lindsay Rosenwald. When the company was founded in 1991, it was founded in multiple parts, in order to best accomplish its goals.
The goal is simple: to seek out companies in the biotechnology, bioresearch, and pharmaceutical development industries who showed great potential, and help them succeed. Success in this industry is nothing simple, however, so Lindsay Rosenwald chose a non-classic structure for the company.
BioSciences is the assessment division the company, created in a way that is meant to seek out companies with great potential in both scientific and commercial aspects. In order to see the greatest success, though, BioCapital was created as an additional division in order to raise capital for these pharmaceutical development companies. The broker company offers a wide range of services, but its specific function is to generate capital while allowing for successful long term investment rather than a focus on short term return on investment. This means that the needed resources for research and development are available for the companies selected by the BioSciences division.
Major broker-dealers, licensors, and CEOs have paid close attention as the group has continued to grow. Many successful members of other large companies have decided to climb on board with the company, eager to see the growing success continue. Lindsay Rosenwald, founder of the company, has allowed the company to function in a way that touches not only the financial, but the scientific aspect of the market, and has created a track record of stunning success. The division of the company into multiple parts, each able to focus on its individual tasks, has shown an ample shareholder return and real impact in the market.
The experience in developing companies of this nature is much of the key to its success. Lindsay Rosenwald has helped to develop more than forty companies to date, including over twenty in the last three years. Helping with capital, infrastructure, and corporate planning has allowed these new companies to overcome obstacles that may have been otherwise insurmountable.
The company is picky, choosing only candidates that represent both commercial potential and scientific significance. While the company is located in New York, they help groups across the United States. One example of a thriving portfolio company is Chelsea Therapeutics. This company’s objective is to find new and innovative solutions for rheumatoid arthritis and inflammatory conditions. As a result the company has achieved its goal. Chelsea Therapeudics has developed a compound which is demonstrably more safe and more effective than other leading treatment.
Another example is the MD Anderson Cancer Center’s arsenic trioxide, a compound for the treatment of cancers, especially solid tumors which require a more aggressive treatment. While other similar treatments have been found to cause significant damage to other parts of the body, arsenic trioxide has not been shown to do so, even in dosages as large as twenty times the normal amount. This particular compound also hold’s the record for the fastest ever approval from the Food and Drug Administration. Lindsay Rosenwald’s has also helped to develop the company Ziopharm Oncology in order to advance and distribute these new treatments.
Keryx Biopharmaceuticals was a company who’s aim was to develop improved compounds for the treatment of diabetes and diabetic nephropathy. It was the investment of Lindsay Rosenwald that allowed for the development of Sulonex, an oral therapy for the treatment of diabetic nephropathy. This compound has revolutionary potential in the medical industry, with as many as 17 million potential patients who have type 1 or 2 diabetes.
With the recent increases in investmen, it is clear that the influence of Lindsay Rosenwald and the companies he has founded will remain significant on the market. With a track record of success, both in the scientific and commercial aspects, it is also clear that this impact will remain positive.
Related posts: